|
1
|
Davidson NE, Armstrong SA, Coussens LM,
Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P,
Kensler TW, Morrow M, et al: AACR cancer progress report 2016. Clin
Cancer Res. 22 (Suppl 19):S1–S137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGuire A, Brown JA, Malone C, McLaughlin
R and Kerin MJ: Effects of age on the detection and management of
breast cancer. Cancers (Basel). 7:908–929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Christenson JL, Butterfield KT, Spoelstra
NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen
BS, Katzenellenbogen JA and Richer JK: MMTV-PyMT and derived Met-1
mouse mammary tumor cells as models for studying the role of the
androgen receptor in triple-negative breast cancer progression.
Horm Cancer. 8:69–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gu G, Dustin D and Fuqua SA: Targeted
therapy for breast cancer and molecular mechanisms of resistance to
treatment. Curr Opin Pharmacol. 31:97–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Riobo-Del Galdo NA, Lara Montero Á and
Wertheimer EV: Role of hedgehog signaling in breast cancer:
Pathogenesis and therapeutic. Cells. 8:E3752019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harbeck N and Gnant M: Breast cancer.
Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu H, Zhang W, Wu Z, Liu Y, Shi Y, Gong J,
Shen W and Liu C: miR-29c-3p regulates DNMT3B and LATS1 methylation
to inhibit tumor progression in hepatocellular carcinoma. Cell
Death Dis. 10:482019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Du H, Xu Q, Xiao S, Wu Z, Gong J, Liu C,
Ren G and Wu H: MicroRNA-424-5p acts as a potential biomarker and
inhibits proliferation and invasion in hepatocellular carcinoma by
targeting TRIM29. Life Sci. 224:1–11. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hausser J and Zavolan M: Identification
and consequences of miRNA-target interactions-beyond repression of
gene expression. Nat Rev Genet. 15:599–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen A, Burgos-Aceves MA and Smith Y:
Estrogen repression of microRNA as a potential cause of cancer.
Biomed Pharmacother. 78:234–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: Metazoan microRNAs. Cell.
173:20–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Quan J, Li Y, Pan X, Lai Y, He T, Lin C,
Zhou L, Zhao L, Sun S, Ding Y, et al: Oncogenic miR-425-5p is
associated with cellular migration, proliferation and apoptosis in
renal cell carcinoma. Oncol Lett. 16:2175–2184. 2018.PubMed/NCBI
|
|
16
|
Zhang JY, Su XP, Li YN and Guo YH:
MicroRNA-425-5p promotes the development of prostate cancer via
targeting forkhead box J3. Eur Rev Med Pharmacol Sci. 23:547–554.
2019.PubMed/NCBI
|
|
17
|
Jiang C, Cao S, Li N, Jiang L and Sun T:
PD-1 and PD-L1 correlated gene expression profiles and their
association with clinical outcomes of breast cancer. Cancer Cell
Int. 19:2332019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang Y, Liu Y, Tan X, Yu S and Luo J:
TPX2 as a novel prognostic indicator and promising therapeutic
target in triple-negative breast cancer. Clin Breast Cancer.
S1526–S8209. Jun 13–2019.(Epub ahead of print).
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Turashvili G and Brogi E: Tumor
heterogeneity in breast cancer. Front Med. 4:2272017. View Article : Google Scholar
|
|
21
|
Hu L, Gao Y, Cao Y, Zhang Y, Xu M, Wang Y,
Jing Y, Guo S, Jing F, Hu X and Zhu Z: Identification of arginine
and its ‘downstream’ molecules as potential markers of breast
cancer. IUBMB Life. 68:817–822. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao S, Zheng J, Liu X, Liu Y, Ruan X, Ma
J, Liu L, Wang D, Yang C, Cai H, et al: FXR1 promotes the malignant
biological behavior of glioma cells via stabilizing MIR17HG. J Exp
Clin Cancer Res. 38:372019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng
Q, Sun J and Wang T: MicroRNA-425-5p regulates chemoresistance in
colorectal cancer cells via regulation of programmed cell death 10.
J Cell Mol Med. 20:360–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang G, Zhang C, Wang N and Chen J:
miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and
suppresses tumorigenesis in osteosarcoma via Wnt/β-catenin
signaling pathway. Int J Biochem Cell Biol. 111:42–51. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Charzewska A, Rzońca S, Janeczko M, Nawara
M, Smyk M, Bal J and Hoffman-Zacharska D: A duplication of the
whole KIAA2022 gene validates the gene role in the pathogenesis of
intellectual disability and autism. Clin Genet. 88:297–299. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Melchior B, Mittapalli GK, Lai C,
Duong-Polk K, Stewart J, Güner B, Hofilena B, Tjitro A, Anderson
SD, Herman DS, et al: Tau pathology reduction with SM07883, a
novel, potent, and selective oral DYRK1A inhibitor: A potential
therapeutic for Alzheimer's disease. Aging Cell. 18:e130002019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu J and Chen H, Ye M, Wang B, Zhang Y,
Sheng J, Meng T and Chen H: Downregulation of long noncoding RNA
HCP5 contributes to cisplatin resistance in human triple-negative
breast cancer via regulation of PTEN expression. Biomed
Pharmacother. 115:1088692019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu L, Wang X, Wang T, Zhu W and Zhou X:
miR-494-3p promotes the progression of endometrial cancer by
regulating the PTEN/PI3K/AKT pathway. Mol Med Rep. 19:581–588.
2019.PubMed/NCBI
|
|
29
|
Shen F, Zheng H, Zhou L, Li W, Liu J and
Xu X: Identification of CD28 and PTEN as novel prognostic markers
for cervical cancer. J Cell Physiol. 234:7004–7011. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang L, Williams MD and Bell D:
Expression of PTEN, androgen receptor, HER2/neu, cytokeratin 5/6,
estrogen receptor-beta, HMGA2, and PLAG1 in salivary duct
carcinoma. Head Neck Pathol. Nov 2–2018.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu L, Zhang C and Liu Q: PTEN
S-nitrosylation by NOS1 inhibits autophagy in NPC cells. Cell Death
Dis. 10:3062019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu
H, Song R, Yang X, Wang Q, Gu S, et al: Loss of PDZK1 expression
activates PI3K/AKT signaling via PTEN phosphorylation in gastric
cancer. Cancer Lett. 453:107–121. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cui C, Li S and Wu D: Znhit1 inhibits
breast cancer by up-regulating PTEN to deactivate the PI3K/Akt/mTOR
pathway. Life Sci. 224:204–211. 2019. View Article : Google Scholar : PubMed/NCBI
|
